Ophthalmoplegia, also referred as extra ocular muscle palsy, is a paralysis of the extra ocular muscles that control movements of eyes. In this condition, nerve fibers that coordinate both eyes in horizontal movements looking from side to side- are damaged. A number of devices and treatments are available in the market, which can cure or improve the eyesight of the patient. The Global ophthalmoplegia market is driven by increasing number of people with ophthalmoplegia and increasing geriatric population. According to the World Health Organization in 2010, about 250 million people of over 50 years were suffering from visual impairment. Around 80% people in many of the developing countries have eye sight problems; of which nearly 50% of the people are not able to take treatment due to huge cost of the surgeries. Increasing prevalence of eye sight affecting diseases, for instance, diabetes and rapid developments in technology have fuelled the growth of the market. On the other hand, high cost of the treatment and availability of cheap alternative treatment may slow the growth of the market. The ophthalmoplegia market is expected to grow at a CAGR of ~ 7.2 % during the forecast period 2017-2023.
Figure: Global Ophthalmoplegia Market by Treatment Market Share, 2016 (%)
The global ophthalmoplegia market has been segmented on the basis of type, treatment and end user.
On the basis of types, the market is segmented into external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia is further segmented into superior recti, inferior recti, medial recti, lateral recti, inferior oblique, and superior oblique muscles.
On the basis of treatment, the market is segmented into surgery, drug treatment, and others. The surgery is further segmented into strabismus surgery and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics, and others.
The Americas dominates the global ophthalmoplegia market owing to well-developed technology and increased patient population with eye sight problem primarily due to increasing prevalence of diabetes. Additionally, high healthcare expenditure and the presence of some of the leading players have fuelled the growth of the market in this region.
Europe is the second largest ophthalmoplegia market, which is followed by Asia Pacific. Increasing government support and availability of funds for research drive the growth of the market. Asia Pacific is the fastest growing ophthalmoplegia market due to increasing geriatric population and rapidly developing medical sector.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities and poor economic and political conditions in Africa.
Some of key players profiled in the report are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US).
The report for the global ophthalmoplegia market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
|Market Size||Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Treatment and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US)|
|Key Market Opportunities||Rapid developments in technology|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Ophtalmoplegia market is predicted to grow at a 7.2% CAGR between 2017-2023.
The Americas is predicted to lead the ophtalmoplegia market.
Major end users of the ophtalmoplegia market include ambulatory clinics, hospitals and clinics, and others.
Key players profiled in the ophtalmoplegia market include Johnson & Johnson (US), ALLERGAN (Ireland), Medline Industries, Inc. (US), Amritt, Inc. (US), Valeant Pharmaceuticals International, Inc. (US), ZEISS International (Germany), Novartis AG (Switzerland), and Abbott (US).
Availability of cheap alternative treatment and high treatment cost may limit the ophtalmoplegia market growth.
1 Report Prologue
2 Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6. Global Ophthalmoplegia Market, by Types
6.1 External ophthalmoplegia
6.1.1 Superior Recti
6.1.2 Inferior Recti
6.1.3 Medial Recti
6.1.4 Lateral Recti,
6.1.5 Inferior Oblique
6.1.6 Superior Oblique Muscles.
6.2 Internuclear opthalmoplegia
7. Global Ophthalmoplegia Market, by Treatments
7.2.1 Strabismus Surgery
7.3 Drug Treatment
8. Global Ophthalmoplegia Market, by End Users
8.2 Hospital & Clinics
8.3 Ambulatory Clinics
9. Global Ophthalmoplegia Market by Region
9.2 North America
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.6 Rest of Middle East & Africa
10 Company Landscape
10.2 Market share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1.1 Company Overview
11.1.2 Product Overview
11.1.4 SWOT Analysis
11.2 Novartis AG
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 ZEISS International
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Valeant Pharmaceuticals International, Inc.
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Amritt, Inc.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Medline Industries, Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7.2 Product Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Ophthalmic Industry